Corvus Pharmaceuticals (CRVS) Cash from Operations (2015 - 2026)

Corvus Pharmaceuticals' Cash from Operations history runs 12 years deep, the most recent figure standing at 10374000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 25.55% year-over-year to 10374000.0; the TTM figure through Mar 2026 stood at 34908000.0 (down 22.36% YoY), while the FY2025 annual figure was 32797000.0, down 29.0% from the prior year.
• Cash from Operations was 10374000.0 for Q1 2026 at Corvus Pharmaceuticals, down from 9191000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5157000.0 in Q1 2024 to a low of 10374000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 7032529.41 across 5 years, with a median of 6424000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations soared 51.59% in 2022, then sank 63.83% in 2024.
• A 5-year view of Cash from Operations shows it stood at 7547000.0 in 2022, then surged by 31.54% to 5167000.0 in 2023, then plunged by 63.83% to 8465000.0 in 2024, then retreated by 8.58% to 9191000.0 in 2025, then fell by 12.87% to 10374000.0 in 2026.
• The last three Cash from Operations figures came in at 10374000.0 (Q1 2026), 9191000.0 (Q4 2025), and 9566000.0 (Q3 2025), per Business Quant data.